Hjem › Akut myeloid leukæmi › Washington › Seattle
Akut myeloid leukæmi kliniske forsøg i Seattle, WA
40 studier for Akut myeloid leukæmi søger deltagere på steder i og omkring Seattle (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.
Officiel studietekst (engelsk)
Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
- Swedish Medical Center-Ballard Campus, Seattle
- Swedish Medical Center-Cherry Hill, Seattle
- Swedish Medical Center-First Hill, Seattle
- og 1 flere
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Swedish Medical Center-First Hill, Seattle
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- Swedish Cancer Institute, Seattle
- Fred Hutchinson Cancer Center, Seattle
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
- Swedish Medical Center-First Hill, Seattle
- University of Washington Medical Center - Montlake, Seattle
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Swedish Medical Center-First Hill, Seattle
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
RekruttererFase 2
- Swedish Medical Center-First Hill, Seattle
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
RekruttererFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RekruttererFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Randomization for the Identification of Best Treatment Intensity for Less Fit Adults With Acute Myeloid Leukemia and Myeloid Neoplasms
Rekrutterer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
RekruttererFase 3
- Seattle Children's Hospital, Seattle
A Home-Based Exercise Intervention (CAREFit-BMT) in Improving Heart Function Among Patients With High Risk Acute Myeloid Leukemia Undergoing Stem Cell Transplant
Rekrutterer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
RekruttererFase 1/2
- Seattle Children's Hospital, Seattle
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
RekruttererFase 3
- Seattle Children's Hospital, Seattle
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
RekruttererFase 1
- University of Washington, Seattle
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
Rekrutterer
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia
RekruttererFase 2
- Fred Hutchinson Cancer Center/University of Washington Cancer Consortium, Seattle
Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RekruttererObservationsstudie
- Fred Hutchinson Cancer Research Center, Seattle
211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia
RekruttererFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome
RekruttererFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
RekruttererFase 2Frivillige med god helbredstilstand velkomne
- Fred Hutch/University of Washington Cancer Consortium, Seattle
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
RekruttererFase 1
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
RekruttererFase 1/2Frivillige med god helbredstilstand velkomne
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
RekruttererFase 2/3
- Seattle Cancer Care Alliance, Seattle
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
RekruttererFase 1/2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
RekruttererFase 1/2
- Fred Hutchinson Cancer Center, Seattle
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
RekruttererFase 2
- Fred Hutchinson Cancer Center, Seattle
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
RekruttererFase 2
- Fred Hutch/University of Washington Cancer Consortium, Seattle
PLAT-08: A Study Of SC-DARIC33 CAR T Cells In Pediatric And Young Adults With Relapsed Or Refractory CD33+ AML
RekruttererFase 1
- Seattle Children's Hospital, Seattle
HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
RekruttererFase 2
- Fred Hutchinson Cancer Research Center, Seattle
Novel Digital Application for Patients With Acute Leukemia
Rekrutterer
- Fred Hutchinson Cancer Research Center (FHCRC), Seattle
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
RekruttererFrivillige med god helbredstilstand velkomne
- Fred Hutchinson Cancer Center, Seattle
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
RekruttererFase 1
- Fred Hutchinson Cancer Center, Seattle
Akut myeloid leukæmi forsøg i andre byer
- Houston, TX85 studier
- New York City, NY51 studier
- Boston, MA44 studier
- Baldwin Park, CA40 studier
- Columbus, OH35 studier
- Philadelphia, PA34 studier
- Durham, NC33 studier
- Atlanta, GA30 studier
- Tampa, FL29 studier
- Chicago, IL26 studier
- Portland, OR25 studier
- Miami, FL24 studier
Andre studier i Seattle
- Ikke-småcellet lungecancer53 studier
- Kræft (alle typer)49 studier
- Prostatakræft42 studier
- Brystkræft39 studier
- Metastatisk cancer39 studier
- Colorektal kræft34 studier
- Lungecancer33 studier
- Ægstockræft30 studier
- Multipelt myelom22 studier
- Myelodysplastiske syndromer21 studier
- Akut lymfoblastisk leukæmi21 studier
- Blærecancer21 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.